Latest Lumos Diagnostics (ASX:LDX) News

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.

Lumos Diagnostics has landed a US$767,800 purchase order for its FebriDx rapid test from PHASE Scientific, marking a key step in commercialising its FDA-approved product ahead of the US flu season.

Xenitra led the healthcare board after a three-year Chinese pharmaceutical deal, while Artrya and InteliCare delivered the week’s biggest contrasting moves. Across the sector, companies raised cash, won regulatory support and pushed deeper into US hospitals and clinics.

Lumos Diagnostics reported a 6% revenue increase to US$13.2 million for FY26, driven by an 875% surge in FebriDx® sales following a pivotal CLIA waiver. The company expanded U.S. adoption to 170+ healthcare sites and secured milestone payments exceeding US$6 million.

Lumos led healthcare stocks higher after widening its US urgent care rollout, while Tissue Repair tumbled on its plan to leave the ASX. Strong trial updates, FDA steps and fresh funding kept the sector busy, even as several stocks fell despite good news.

Lumos Diagnostics is accelerating the rollout of its rapid FebriDx test in the US, with a top 100 urgent care group deploying across 30+ sites and three tier 1 groups validating the test across 230+ locations.

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.

Lumos Diagnostics has received a A$709,837 cash refund from the Australian Government’s R&D Tax Incentive, bolstering its investment in proprietary point-of-care diagnostic technologies.

Imugene, Vitasora and Adherium led a volatile week in healthcare shares, as trial news and software rollouts battled capital raisings, legal issues and weak sentiment in smaller biotech names. Big contracts, takeover steps and record earnings kept the sector busy, but several stocks still fell even after reporting clear operational progress.

Lumos Diagnostics advances US commercial rollout of FebriDx with positive reimbursement data and expanded urgent care adoption ahead of the 2027/28 flu season.

Lumos Diagnostics has reached a key enrolment milestone in its BARDA-backed FebriDx paediatric trial, unlocking a US$670,000 payment and advancing its FDA submission pathway to expand use in children aged 2-12 years.

Healthcare stocks delivered a mix of capital raisings, product approvals and trial wins, but many early share price jumps did not last. The biggest moves came from Patrys, Firebrick Pharma and 4DMedical, where investors reacted fast to funding news and then kept testing how much near-term value was really on offer.